| [26] |
Mrugala MM, Engelhard HH, Dinh Tran D, et al. Clinical practice experience with NovoTTF-100ATM system for glioblastoma: the patient registry dataset (PRiDe)[J]. Semin Oncol, 2014, 41 Suppl 6: S4-S13.
|
| [27] |
Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial[J]. JAMA, 2017, 318(23): 2306-2316.
|
| [28] |
Giladi M, Munster M, Schneiderman RS, et al. Tumor treating fields (TTfields) delay DNA damage repair following radiation treatment of glioma cells[J]. Radiat Oncol, 2017, 12(1): 206.
|
| [29] |
Guberina N, Pottgen C, Kebir S, et al. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial[J]. Radiat Oncol, 2020, 15(1): 83.
|
| [30] |
Lazaridis L, Schafer N, Teuber-Hanselmann S, et al. Tumour treating fields (TTfields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma[J]. J Cancer Res Clin Oncol, 2020, 146(3): 787-792.
|
| [31] |
Stewart G, Eugene H, Lai JS, et al. Pdct-07. Feasibility trial of ttfields (tumor treating fields) for children with recurrent or progressive supratentorial high-grade glioma (HGG) and ependymoma: a pediatric brain tumor consortium study: PBTC-048[J]. Neuro Oncol, 2018, 20(Suppl 6): vi201-vi202
|
| [32] |
Tran D, Warren S, Friedman W, et al. Path-27. Identifying the genetic signature of response in a phase II study of tumor treating fields in recurrent glioblastoma[J]. Neuro Oncol, 2018, 20(Suppl 6): vi164.
|
| [33] |
Bhr O, Tabatabai G, Fietkau R, et al. P14.63 The use of TTFields for newly diagnosed GBM patients in Germany in routine clinical care (TIGER: TTFields in Germany in routine clinical care)[J]. Neuro Oncol, 2019, 21(Suppl 3): iii82.
|
| [34] |
Wick W. TTFelds: where does all the skepticism come from?[J]. Neuro Oncol, 2016, 18(3): 303-305.
|
| [35] |
Cloughesy TF, Lassman AB. NovoTTF: where to go from here?[J]. Neuro Oncol, 2017, 19(5): 605-608.
|
| [36] |
Burri SH, Gondi V, Brown PD, et al. The evolving role of tumor treating fields in managing glioblastoma: guide for oncologists[J]. Am J Clin Oncol, 2018, 41(2): 191-196.
|
| [37] |
Bernard-Arnoux F, Lamure M, Ducray F, et al. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma[J]. Neuro Oncol, 2016, 18(8): 1129-1136.
|
| [38] |
Toms SA, Kim CY, Nicholas G, et al. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial[J]. J Neurooncol, 2019, 141(2): 467-473.
|
| [1] |
Brat DJ, Prayson RA, Ryken TC, et al. Diagnosis of malignant glioma: role of neuropathology[J]. J Neurooncol, 2008, 89(3): 287-311.
|
| [2] |
Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of brain tumors[J]. Neurol Clin, 2018, 36(3): 395-419.
|
| [3] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
| [4] |
Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?[J]. Neuro Oncol, 2013, 15(1): 4-27.
|
| [5] |
Mun EJ, Babiker HM, Weinberg U, et al. Tumor-treating fields: a fourth modality in cancer treatment[J]. Clin Cancer Res, 2018, 24(2): 266-275.
|
| [6] |
Chaudhry A, Benson L, Varshaver M, et al. NovoTTFTM-100A system (tumor treating fields) transducer array layout planning for glioblastoma: a NovoTALTM system user study[J]. World J Surg Oncol, 2015, 13: 316.
|
| [7] |
Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality[J]. Eur J Cancer, 2012, 48(14): 2192-2202.
|
| [8] |
Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(11): 1537-1570.
|
| [9] |
国家卫生健康委员会医政医管局.脑胶质瘤诊疗规范(2018年版)[J].中华神经外科杂志, 2019, 35(3): 217-239.
|
| [10] |
Kirson ED, Dbaly V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors[J]. Proc Natl Acad Sci USA, 2007, 104(24): 10152-10157.
|
| [11] |
Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors[J]. Onkologie, 2008, 31(7): 362-365.
|
| [12] |
Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields[J]. Cancer Res, 2004, 64(9): 3288-3295.
|
| [13] |
Gutin PH, Wong ET. Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality[J]. Am Soc Clin Oncol Educ Book, 2012: 126-131.
|
| [14] |
Gera N, Yang A, Holtzman TS, et al. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit[J]. PLoS One, 2015, 10(5): e0125269.
|
| [15] |
Wenger C, Salvador R, Basser PJ, et al. The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study[J]. Phys Med Biol, 2015, 60(18): 7339-7357.
|
| [16] |
Kim CY, Paek SH, Nam DH, et al. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial[J]. J Neurooncol, 2020, 146(3): 399-406.
|
| [17] |
Karanam NK, Srinivasan K, Ding L, et al. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines[J]. Cell Death Dis, 2017, 8(3): e2711.
|
| [18] |
Karanam NK, Ding L, Aroumougame A, et al. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: implications for cancer therapy[J]. Transl Res, 2020, 217: 33-46.
|
| [19] |
Shteingauz A, Porat Y, Voloshin T, et al. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to tumor treating fields (TTfields)[J]. Cell Death Dis, 2018, 9(11): 1074.
|
| [20] |
Voloshin T, Kaynan N, Davidi S, et al. Tumor-treating fields (TTfields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy[J]. Cancer Immunol Immunother, 2020, 69(7): 1191-1204.
|
| [21] |
Kim EH, Song HS, Yoo SH, et al. Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis[J]. Oncotarget, 2016, 7(40): 65125-65136.
|
| [22] |
Chang E, Patel CB, Pohling C, et al. Tumor treating fields increases membrane permeability in glioblastoma cells[J]. Cell Death Discov, 2018, 4: 113.
|
| [23] |
Winkler F, Osswald M, Wick W. Anti-angiogenics: their role in the treatment of glioblastoma[J]. Oncol Res Treat, 2018, 41(4): 181-186.
|
| [24] |
Kochar AS, Madhavan M, Manjila S, et al. Contemporary updates on clinical trials of antiangiogenic agents in the treatment of glioblastoma multiforme[J]. Asian J Neurosurg, 2018, 13(3): 546-554.
|
| [25] |
Akers KG, Martinez-Canabal A, Restivo L, et al. Hippocampal neurogenesis regulates forgetting during adulthood and infancy[J]. Science, 2014, 344(6184): 598-602.
|